Loading
Everything in development, the medicines held by this cancer's subtypes, the open problems and what is being done about them, the roadmaps, and what changed on this record.
What is in development for Mismatch repair deficient (MSI-high) pancreatic ductal adenocarcinoma, drawn from the whole corpus: 5 items. Drugs are grouped by the most advanced trial phase they have reached anywhere; approved treatments sit under standard of care. Technologies are the methods being tested for this cancer, trials are the studies recorded here, and ideas are proposals not yet in a trial.
Response rates to PD-1 blockade are lower than in colorectal cancer and the reasons are not settled.
Whether checkpoint inhibitors should replace chemotherapy first line is untested in the pancreas.
Immunohistochemistry misses some deficient tumours and over-calls others; confirmatory sequencing is not universal.
Lynch syndrome carriers have no proven pancreatic surveillance strategy.
Dated changes read from the records linked to this cancer: approvals, regulatory steps, reported trials, guideline versions and milestones. Newest first; no date is inferred.
On EdgeAll 14 changes by month →When this page itself was last checked or edited.
Untreated unresectable or metastatic MSI-high or dMMR colorectal cancer, with nivolumab
Untreated unresectable or metastatic MSI-high or dMMR colorectal cancer, with ipilimumab
Unresectable or metastatic MSI-high or dMMR colorectal cancer, with ipilimumab
Previously treated MSI-high or dMMR endometrial, biliary, colorectal, gastric or small intestine cancer
Mismatch repair deficient or MSI-high tumours: NICE TA914 (20 September 2023) covers previously treated endometrial, gastric, small intestine, biliary and colorectal cancer and does not include pancreatic cancer